Dexfenfluramine
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. It was for some years in the mid-1990s approved by the United States Food and Drug Administration for the purposes of weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. After it was removed in the US, dexfenfluramine was also pulled out in other global markets. It was later superseded by sibutramine, which is a safer alternative to both dexfenfluramine and fenfluramine.
The drug was manufactured by Interneuron Pharmaceuticals and marketed by Wyeth-Ayerst Laboratories. It is the enantiomer of levofenfluramine.
See also
References
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH